Prolonged bleeding after trauma with normal PT and PTT. Dx and tx?

Prolonged bleeding after trauma with normal PT and PTT. Dx and tx?

• A. Hemophilia A; Desmopressin
• B. Platelet function disorder; Platelet transfusion
• C. Hemophilia B; FFP
• D. Von Willebrand disease; Desmopressin mainstay; Factor VII concentrate if type 2 or 3

Answer: (D)

When bleeding after trauma occurs but routine coagulation tests are normal, the issue is often not the clotting factors themselves but the platelet–vessel wall interaction. Von Willebrand disease is the most common inherited bleeding disorder and specifically impairs platelet adhesion to damaged endothelium, while also stabilizing factor VIII. This pattern fits a scenario where bleeding is prominent but prothrombin time and partial thromboplastin time remain normal. Desmopressin is the primary treatment because it causes release of von Willebrand factor from endothelial stores, increasing both vWF and factor VIII levels and improving platelet adhesion. It works well for many patients with milder von Willebrand disease (especially type 1 and some type 2). If desmopressin isn’t effective or in patients with type 2 or type 3 disease (where vWF is deficient or dysfunctional), replacing the missing von Willebrand factor with concentrates that contain vWF (often combined with factor VIII) is used to achieve hemostasis. Factor VII concentrate is not the standard therapy for von Willebrand disease. How this contrasts with the other options: a deficiency of factor VIII or IX (hemophilia A or B) typically shows an abnormal intrinsic pathway test (prolonged PTT) and bleeding tends to be deeper tissue or joint-related rather than mucosal; platelet function disorders can cause mucosal bleeding but the first-line pharmacologic therapy in a typical von Willebrand presentation is desmopressin to boost endogenous vWF, with concentrates if needed.

When bleeding after trauma occurs but routine coagulation tests are normal, the issue is often not the clotting factors themselves but the platelet–vessel wall interaction. Von Willebrand disease is the most common inherited bleeding disorder and specifically impairs platelet adhesion to damaged endothelium, while also stabilizing factor VIII. This pattern fits a scenario where bleeding is prominent but prothrombin time and partial thromboplastin time remain normal.

Desmopressin is the primary treatment because it causes release of von Willebrand factor from endothelial stores, increasing both vWF and factor VIII levels and improving platelet adhesion. It works well for many patients with milder von Willebrand disease (especially type 1 and some type 2). If desmopressin isn’t effective or in patients with type 2 or type 3 disease (where vWF is deficient or dysfunctional), replacing the missing von Willebrand factor with concentrates that contain vWF (often combined with factor VIII) is used to achieve hemostasis. Factor VII concentrate is not the standard therapy for von Willebrand disease.

How this contrasts with the other options: a deficiency of factor VIII or IX (hemophilia A or B) typically shows an abnormal intrinsic pathway test (prolonged PTT) and bleeding tends to be deeper tissue or joint-related rather than mucosal; platelet function disorders can cause mucosal bleeding but the first-line pharmacologic therapy in a typical von Willebrand presentation is desmopressin to boost endogenous vWF, with concentrates if needed.